IIMMIOS is a pre-clinical stage company developing IMS-2407 antibody to reset tissue auto-immune disease providing durable relapse-free benefit to patients suffering from auto-immune and inflammatory disease. Our lead program is set-up to file IND/CTA YE 2026 and deliver proof of mechanism in patients (in two indications) in 2028. Portfolio development is ongoing to identify second program following IMS-2407.
#autoimmune disease
#antibody development
#Series A fundraise
#immune reset
Company Details
- Employees
- 18
- Founded
- -
- Address
- Kloosterstraat 9, Re3144,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.IMMIOS-biotech.com
- HQ
- Oss
Immios B.v. Questions
Immios B.V.'s website is http://www.IMMIOS-biotech.com
Immios B.V.'s LinkedIn profile is https://nl.linkedin.com/company/immios-b-v
Immios B.V. has
18 employees.
View email and phone details for 18
employees at Immios B.V..
Immios B.V.'s industry is
Biotechnology Research
Immios B.V.'s top competitors are
Flindr (Formerly Immagene),
Sairopa B.v.,
Scenic Biotech,
Lava Therapeutics N.v.,
M3 Pharma Consultancy,
Flindr Therapeutics,
Acerta Pharma B.v. (A Member Of The Astrazeneca Group),
Stant,
Kling Biotherapeutics,
Absano B.v..
Immios B.V.'s categories are Biotechnology Research
Immios B.V.'s founding year is 2022
